LINEAS DE INVESTIGACIÓN

TRATAMIENTO MOLECULAR DIRIGIDO DE LEUCEMIAS AGUDAS U CRONICAS, LINFOMAS, ANGIOGENESIS EN NEOPLASIAS HEMATOLOGICAS MALIGNAS, LEUCEMIA MIELOIDE CRONICA, CÁNCER DE PANCREAS, TUMORES NEUROENDOCRINOS.


PUBLICACIONES RELEVANTES DE LOS ULTIMOS 5 AÑOS

Perez-Jacobo F, Tuna-Aguila E, Demichelis-Gomez R, Crespo-Solis E, Valencia-Rocha U, Aguayo A, Lopez-Karpovitch X. Prognostic Factors, Response to Treatment and Survival in Patients With Chronic Myeloid Leukemia in Blast Phase A Single-Institution Survey. Clin Lymphoma Myeloma Leuk 2015; 15(12): 778-84.

Experts in Chronic Myeloid Leukemia . The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: From the perspective of a large group of CML experts. Blood 2013; 121(22):4439-42.

Aguayo A, Coban S. State-of-the-art in the management of chronic myelogenous leukemia in the era of tyrosine kinase inhibitors: evolutionary trends in diagnosis, monitoring and treatment. Leuk Lymphoma 2009; Suppl2: 1.8

Aguayo A. VEGF in chronic myeloid leukemia treated with interferon and imatinib. Leuk Res 2014; 38(6):660-1

Aguayo A. VEGF in central Nervous Leukemia. Leuk Res 2013; 37(4):357-8.